Thelansis

  Chronic Graft-Versus-Host Disease (cGVHD) lasts more than three months after transplantation and is the most common late complication of allogeneic HSCT, accounting for approximately 25% of pediatric patients. Chronic GVHD is the primary cause of nonrelapse mortality and morbidity in long-term HSCT survivors. cGVHD typically manifests with multiorgan pathology and historically has been defined temporally as GVHD that occurred later than 100 days post-SCT. Chronic GVHD has a wide prevalence ranging from 6% to 80%, depending on donor type, recipient age, and the source of the transplanted hemopoietic cells. Chronic GVHD is diagnosed by distinguishing it from acute GVHD, having at least one diagnostic clinical sign of chronic GVHD, or having at least one distinctive manifestation confirmed by pertinent biopsy or other relevant tests in the same or another organ, and ruling out other possible diagnoses. Chronic GVHD symptoms can appear in the skin, oral and gut mucosa, eyes, lungs, f...